Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of DCTY1102 Injection in the Treatment of Participants With Advanced Malignant Tumors Harboring KRAS/NRAS G12D Mutation Positivity and HLA-A*11:01 Genotype

NCT07014878 is registered in ClinicalTrials.gov with Beijing DCTY Biotech Co.,Ltd. as lead sponsor.

NCT NCT07014878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07014878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of DCTY1102 Injection in the Treatment of Participants With Advanced Malignant Tumors Harboring KRAS/NRAS G12D Mutation Positivity and HLA-A*11:01 Genotype
Lead sponsor
Beijing DCTY Biotech Co.,Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
August 31, 2028
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, lung cancer, pancreatic cancer